

Appendix 3Y

Change of Director's Interest Notice

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.

Introduced 30/09/01 Amended 01/01/11

Name of entity: CHEMGENEX PHARMACEUTICALS LIMITED
ABN: 79 000 248 304

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

Name of Director	Jean-Luc Tétard
Date of last notice	22 October 2010

Part 1 - Change of director's relevant interests in securities

In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust

Note: In the case of a company, interests which come within paragraph (i) of the definition of "notifiable interest of a director" should be disclosed in this part.

Direct or indirect interest	Indirect
Nature of indirect interest (including registered holder) <small>Note: Provide details of the circumstances giving rise to the relevant interest.</small>	37,235,343 fully paid ordinary shares (ASX Code: CXS) held by Stragen Investments N.V.
Date of change	1 April 2011
No. of securities held prior to change	37,235,343 fully paid ordinary shares (ASX Code: CXS) held by Stragen Investments N.V.; 250,000 unlisted options exercisable at \$1.15 (held directly)
Class	Fully paid ordinary shares (ASX Code: CXS)
Number acquired	N/A
Number disposed	34,254,463
Value/Consideration <small>Note: If consideration is non-cash, provide details and estimated valuation</small>	\$23,978,124.10 (\$0.70 cents per fully paid ordinary share)
No. of securities held after change	2,980,880 fully paid ordinary shares (ASX Code: CXS) held by Stragen Investments N.V.; 250,000 unlisted options exercisable at \$1.15 (held directly)

+ See chapter 19 for defined terms.

Appendix 3Y
Change of Director's Interest Notice

Nature of change <small>Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy-back</small>	Cephalon International Holdings, Inc exercised its option to acquire 34,254,463 fully paid ordinary shares at the price of \$0.70 per share from Stragen International N.V.
--	---

Part 2 – Change of director's interests in contracts

Note: In the case of a company, interests which come within paragraph (ii) of the definition of "notifiable interest of a director" should be disclosed in this part.

Detail of contract	N/A
Nature of interest	N/A
Name of registered holder (if issued securities)	N/A
Date of change	N/A
No. and class of securities to which interest related prior to change <small>Note: Details are only required for a contract in relation to which the interest has changed</small>	N/A
Interest acquired	N/A
Interest disposed	N/A
Value/Consideration <small>Note: If consideration is non-cash, provide details and an estimated valuation</small>	N/A
Interest after change	N/A

Part 3 – +Closed period

Were the interests in the securities or contracts detailed above traded during a +closed period where prior written clearance was required?	No
If so, was prior written clearance provided to allow the trade to proceed during this period?	N/A
If prior written clearance was provided, on what date was this provided?	N/A



James Campbell
 Company Secretary
 1 April 2011

+ See chapter 19 for defined terms.